Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120317) titled 'The hepatoprotective effect of dexmedetomidine in liver tumor patients undergoing surgical resection: A randomized controlled trial' on March 12.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Fudan University Shanghai Cancer Center
Condition:
Ischemia-reperfusion injury
Intervention:
Dexmedetomidine group (DEX):A loading dose of 0.5 µg/kg was administered over 10 minutes before the start of surgery, followed by a maintenance dose of 0.5 µg/kg/h, which was discontinued 30 minutes before the end of surgery.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First...